Information Provided By:
Fly News Breaks for November 12, 2019
Nov 12, 2019 | 12:41 EDT
Credit Suisse analyst Martin Auster said news that the FDA placed a clinical hold on Solid Biosciences' SGT-001 trial after the third patient in the high dose cohort experienced a serious adverse event may be the "final straw" for a program that had already been placed on clinical hold previously. He has cut his view of the probability of success for SGT-001 to 5% from 10% and cut his price target on Solid shares to $2 from $6. Auster has an Underperform rating on Solid Biosciences shares.
News For SLDB From the Last 2 Days
There are no results for your query SLDB